UBC Faculty Research and Publications

Effects of a Web-Based Patient Decision Aid on Biologic and Small Molecule Agents for Rheumatoid Arthritis : Results From a Proof-of-Concept Study Li, Linda C.; Shaw, Chris D.; Lacaille, Diane; Yacyshyn, Elaine; Jones, C. Allyson; Koehn, Cheryl; Hoens, Alison; Geldman, Jasmina; Sayre, E. C.; Macdonald, Graham G.; Leese, Jenny; Bansback, Nick


Objective. To assess the extent to which ANSWER-2, an interactive online patient decision aid, reduces patients’ decisional conflict and improves their medication-related knowledge and self-management capacity. Methods. We used a pre–post study design. Eligible participants had a diagnosis of rheumatoid arthritis (RA), had been recommended to start using a biologic agent or small-molecule agent or to switch to a new one, and had internet access. Access to ANSWER-2 was provided immediately after enrollment. Outcome measures included 1) the Decisional Conflict Scale (DCS), 2) the Medication Education Impact Questionnaire (MeiQ), and 3) the Partners in Health Scale (PIHS). A paired t-test was used to assess differences pre and postintervention. Results. The majority of the 50 participants were women (n = 40), and the mean ± SD age of participants was 49.6 ± 12.2 years. The median disease duration was 5 years (25th, 75th percentile: 2, 10 years). The mean ± SD DCS score was 45.9 ± 25.1 preintervention and 25.1 ± 21.8 postintervention (mean change of -21.2 of 100 [95% confidence interval (95% CI) -28.1, -14.4], P < 0.001). Before using ANSWER-2, 20% of participants had a DCS score of

Item Citations and Data


Attribution-NonCommercial-NoDerivatives 4.0 International

Usage Statistics